Biohaven Receives $80,000,000 New Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5e253804-c186-4329-8509-97ba1ad8d714 - Date
11/2/2016 - Company Name
Biohaven - Mailing Address
234 Church Street New Haven, CT 06510 USA - Company Description
Biohaven is a privately-held biopharmaceutical company with particular expertise in late stage clinical development and has portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC, Massachusetts General Hospital and two undisclosed pharmaceutical companies. - Website
http://www.biohavenpharma.com - Transaction Type
Venture Equity - Transaction Amount
$80,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds from this financing will be used to advance the company’s late stage clinical programs in orphan neurologic indications and other trials in areas of large unmet medical needs. Biohaven plans to initiate Phase 2/3 studies in 4Q2016 and in 2017. - M&A Terms
- Venture Investor
Venrock - Venture Investor
RA Capital - Venture Investor
Vivo Capital - Venture Investor
Aisling Capital - Venture Investor
Rock Springs Capital - Venture Investor
Investor - Venture Investor
Knollwood Investment Advisory - Venture Investor
Osage Partners - Venture Investor
Aperture Venture Partners - Venture Investor
Connecticut Innovations - Venture Investor
Investor - Venture Investor
Undisclosed
